AI
Commented by Fabian Lorenz on November 14th, 2025 | 07:15 CET
AI fantasy, takeover rumors, and a 14% dividend: TKMS, TeamViewer, RE Royalties
Investors can currently expect a 14% dividend yield when buying RE Royalties shares. In addition, the price seems far too low. After all, the Company is increasingly financing renewable energy projects in the US, and the market is booming due to the energy hunger of AI data centers. TeamViewer's stock has not boomed for quite some time. Even after the price halved, the stock has not found a bottom. Can AI fantasy cause investors to rethink their position? TKMS has recently held up well in the sell-off of defense stocks. Now there are takeover rumors. Accordingly, the stock market newcomer is about to take over its neighboring shipyard.
Read
Commented by Fabian Lorenz on November 14th, 2025 | 07:05 CET
Critical stocks on sale? Standard Lithium, European Lithium, D-Wave, BASF!
Are critical raw materials suddenly in abundance? Looking at the price performance of many stocks in the sector, this thought may come to mind. Many stocks have lost 50% or more since mid-October. The truth is that they had often more than doubled in value in the weeks prior to that. China's export ban led to excesses that now need to be corrected. Nevertheless, the fundamental driver of the sector remains intact: the West must not be vulnerable to blackmail when it comes to critical raw materials. This means that stocks such as European Lithium and Standard Lithium remain attractive to investors. And what is BASF doing? The Company exemplifies the problems facing the German chemical industry. Can D-Wave Quantum help?
Read
Commented by André Will-Laudien on November 13th, 2025 | 07:20 CET
Record stock market! And the momentum continues with Palantir, D-Wave, Gerresheimer, and NetraMark
Artificial intelligence (AI) is fundamentally changing drug development by analyzing vast amounts of data in record time and controlling clinical trials more precisely. Advanced systems identify promising drug candidates and predict therapeutic success with impressive accuracy. Companies such as NetraMark are already successfully using these technologies to accelerate development processes. At the same time, the well-known AI stars Palantir and D-Wave are driving the next wave of innovation as pacemakers in data analysis and quantum computing, recording extraordinary share price gains. The German Gerresheimer Group is also increasingly integrating AI-supported solutions into the manufacture of pharmaceutical packaging and medical technology. For investors, this represents a pool of opportunities, but the choice remains difficult!
Read
Commented by Fabian Lorenz on November 11th, 2025 | 07:20 CET
D-Wave price target doubled! Is the US losing the AI race? Plug Power and First Hydrogen shares benefit!
Despite giants like Nvidia and OpenAI, is the US losing the race for the best artificial intelligence to China? Increasingly, experts are warning that this could be the case. The reason: the US could face an energy problem. Much less GW of capacity is being fed into the grid than in China. In the search for beneficiaries, Plug Power has recently been highlighted. The Company is now attractively valued again. In contrast, First Hydrogen appears to have catch-up potential and could even attract takeover interest. Beyond AI, quantum technology is electrifying the stock market. After D-Wave's stock recently underwent a sharp correction, analysts have now doubled the price target.
Read
Commented by Stefan Feulner on November 11th, 2025 | 07:00 CET
Vistra, NetraMark, Snap – AI stocks with potential
The bull market of recent months has given way to disillusionment, as AI stocks were sold off last week despite strong quarterly results. Is hedge fund manager Michael Burry, famous from "The Big Short," right again? According to the latest 13F filing from Scion Asset Management, Burry holds put options on Nvidia and Palantir with a total value of around USD 1.1 billion and is betting on sharply falling prices. He points to the exceptionally high valuations of these companies as the reason for his pessimism. However, not all stocks in the field of artificial intelligence are overpriced. Some promising names with significant upside potential can still be found among the second-tier players.
Read
Commented by Carsten Mainitz on November 6th, 2025 | 07:05 CET
Totally underestimated! These are the secret winners of the AI and energy revolution: Power Metallic Mines, Aixtron, and Siemens Energy!
Forget most of the hyped stocks in the AI and tech space. The most significant gains in the current tech and energy transition boom come - not from the diggers, but from the suppliers - just like during the Gold Rush in the 19th century. While billions are being poured into the hunt for digital gold (artificial intelligence) and green gold (renewable energy), the (emerging) raw material producers, specialized machinery manufacturers, and infrastructure providers are the ones benefiting most. We show you the overlooked profiteers of the boom!
Read
Commented by Fabian Lorenz on November 6th, 2025 | 07:00 CET
Does Germany have a drone problem? Hensoldt, TKMS, Helsing, and NEO Battery Materials!
Drone alerts at German and European airports! At the same time, criticism of Germany's defense policy is growing louder. Is the federal government investing too much in tanks and other heavy equipment and too little in drones and counter-drone systems? This opinion is shared not only by the head of Germany's new drone star, Helsing, but also by several other experts. The situation is quite different in the rest of the world, where demand for drones is rising significantly. NEO Battery Materials is also benefiting from this trend. The Company recently secured an existing factory in South Korea for the production of high-performance batteries, and the first million-dollar orders are already in place. And what is TKMS doing? Its share price has slipped in recent days. Could large orders bring new momentum?
Read
Commented by Fabian Lorenz on November 5th, 2025 | 07:10 CET
Millions for BioNTech and Evotec! But drug development is costly! Is NetraMark the next takeover target?
NetraMark scores again. The Company's AI has convinced yet another biopharma company and is increasingly shaping up as a potential takeover target. The new client will use NetraAI to optimize its clinical trial, cutting both time and costs. The high expense of drug development is clear: BioNTech invested EUR 565 million into its pipeline last quarter. However, the German biotech leader can afford this thanks to billions in its coffers. Analysts still recommend buying the stock. By contrast, even a million-dollar payment from a partner could not give Evotec shares any real momentum. Could today’s figures finally spark a turnaround?
Read
Commented by Armin Schulz on November 4th, 2025 | 07:05 CET
The three stocks for the AI revolution: How to profit with Alibaba, Aspermont, and Palantir
In an era where autonomous AI agents manage complex processes and data-driven decisions generate over 50% more growth, technological advancement determines market dominance. Even traditional industries such as mining are experiencing a revolution through real-time data. Investing in this future means backing the right pioneers. Three companies, Alibaba, Aspermont, and Palantir, exemplify how these megatrends can be capitalized on.
Read
Commented by Armin Schulz on October 30th, 2025 | 07:25 CET
A new era in medicine is dawning: How Novo Nordisk, NetraMark Holdings, and Bayer are benefiting from AI and personalization
The healthcare industry is on the cusp of a new era, driven by AI-powered personalized therapies that are not only prolonging lives but also reshaping markets worth billions. Those who identify the pioneers of this transformation early on could benefit from extraordinary growth opportunities. Three companies, Novo Nordisk, NetraMark Holdings, and Bayer, are positioning themselves at the heart of this profitable field with groundbreaking technologies and therapies.
Read